MX383947B - Composiciones de colágeno 7 y métodos para usar las mismas. - Google Patents

Composiciones de colágeno 7 y métodos para usar las mismas.

Info

Publication number
MX383947B
MX383947B MX2018007468A MX2018007468A MX383947B MX 383947 B MX383947 B MX 383947B MX 2018007468 A MX2018007468 A MX 2018007468A MX 2018007468 A MX2018007468 A MX 2018007468A MX 383947 B MX383947 B MX 383947B
Authority
MX
Mexico
Prior art keywords
collagen
compositions
methods
same
present disclosure
Prior art date
Application number
MX2018007468A
Other languages
English (en)
Other versions
MX2018007468A (es
Inventor
Amey Bandekar
Bing He
Igor Quinones-Garcia
Kris Lowe
Lin Guey
Sujit Basu
Vinh Nguyen
Original Assignee
Phoenix Tissue Repair Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phoenix Tissue Repair Inc filed Critical Phoenix Tissue Repair Inc
Publication of MX2018007468A publication Critical patent/MX2018007468A/es
Publication of MX383947B publication Critical patent/MX383947B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/014—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/20—Halogens; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/24—Phosphorous; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4993—Derivatives containing from 2 to 10 oxyalkylene groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Birds (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Materials For Medical Uses (AREA)

Abstract

La presente invención se refiere a composiciones que comprenden colágeno 7 y con métodos para usar las mismas para tratar DEB.
MX2018007468A 2015-12-23 2016-12-21 Composiciones de colágeno 7 y métodos para usar las mismas. MX383947B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562387241P 2015-12-23 2015-12-23
US201662278816P 2016-01-14 2016-01-14
US201662293209P 2016-02-09 2016-02-09
PCT/US2016/067995 WO2017112757A1 (en) 2015-12-23 2016-12-21 Collagen 7 compositions and methods of using the same

Publications (2)

Publication Number Publication Date
MX2018007468A MX2018007468A (es) 2018-11-14
MX383947B true MX383947B (es) 2025-03-14

Family

ID=59091196

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018007468A MX383947B (es) 2015-12-23 2016-12-21 Composiciones de colágeno 7 y métodos para usar las mismas.

Country Status (7)

Country Link
US (3) US10695395B2 (es)
EP (1) EP3394095B1 (es)
JP (3) JP6943858B2 (es)
CN (2) CN114225013A (es)
IL (2) IL259583B (es)
MX (1) MX383947B (es)
WO (1) WO2017112757A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX383947B (es) * 2015-12-23 2025-03-14 Phoenix Tissue Repair Inc Composiciones de colágeno 7 y métodos para usar las mismas.
TWI818166B (zh) * 2019-03-27 2023-10-11 美商菲尼克斯組織修復公司 用於生產膠原蛋白7組合物之系統及方法
US20240424065A1 (en) 2021-10-12 2024-12-26 Phoenix Tissue Repair, Inc. Collagen 7 protein replacement therapy

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2757874B1 (fr) * 1996-12-17 2003-04-25 Biocem Collagenes recombinants et proteines derivees produits par les plantes, leurs procedes d'obtention et leurs utilisations
PL215168B1 (pl) * 2002-02-27 2013-10-31 Immunex Corp Formulacja polipeptydowa
GB0216001D0 (en) * 2002-07-10 2002-08-21 Nat Blood Authority Process and composition
US20080287349A1 (en) * 2003-05-09 2008-11-20 Jeffrey Peterson Fibroblast growth factor 20 and methods of use thereof
ES2676644T3 (es) * 2003-12-19 2018-07-23 Novo Nordisk Health Care Ag Composiciones estabilizadas de polipéptidos de factor VII
JP4832107B2 (ja) * 2006-02-23 2011-12-07 ソニーケミカル＆インフォメーションデバイス株式会社 実装方法
CN103540575A (zh) * 2006-08-01 2014-01-29 奇尼塔二有限责任公司 医药制造方法
US20120121580A1 (en) * 2009-07-28 2012-05-17 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
US8475824B2 (en) * 2010-01-26 2013-07-02 Warsaw Orthopedic, Inc. Resorbable matrix having elongated particles
WO2011113024A1 (en) * 2010-03-11 2011-09-15 University Of Southern California Compositions and methods for healing of skin wounds
WO2011140526A1 (en) * 2010-05-06 2011-11-10 University Of Southern California Usc Stevens Methods and agents for enhancing wound healing
EP2699265B1 (en) * 2011-04-20 2019-10-16 Sandoz AG STABLE PHARMACEUTICAL LIQUID FORMULATIONS OF THE FUSION PROTEIN TNFR:Fc
JP2014532713A (ja) * 2011-11-02 2014-12-08 ハルシオン，インコーポレイテッド 創傷処置の方法及び組成物
US12558316B2 (en) * 2013-03-13 2026-02-24 University Of Miami Methods and compositions for the treatment of epidermolysis bullosa
CN104740612A (zh) * 2013-12-31 2015-07-01 上海中信国健药业股份有限公司 一种受体抗体融合蛋白的液体制剂
AU2015243535A1 (en) * 2014-04-08 2016-11-03 University Of Southern California Polypeptide compositions with Type VII collagen fibronectin Type Ill- like repeats and treatment methods for wound closure and healing
MX383947B (es) * 2015-12-23 2025-03-14 Phoenix Tissue Repair Inc Composiciones de colágeno 7 y métodos para usar las mismas.
WO2017160636A1 (en) * 2016-03-16 2017-09-21 Shire Human Genetic Therapies, Inc. Methods of purifying collagen 7

Also Published As

Publication number Publication date
US20230414698A1 (en) 2023-12-28
CN108463470A (zh) 2018-08-28
CN108463470B (zh) 2021-10-22
JP2023166014A (ja) 2023-11-17
IL259583A (en) 2018-07-31
JP2021185201A (ja) 2021-12-09
WO2017112757A1 (en) 2017-06-29
EP3394095B1 (en) 2023-09-27
US20190000912A1 (en) 2019-01-03
CN114225013A (zh) 2022-03-25
CA3006998A1 (en) 2017-06-29
EP3394095A1 (en) 2018-10-31
US20200316158A1 (en) 2020-10-08
JP6943858B2 (ja) 2021-10-06
MX2018007468A (es) 2018-11-14
US10695395B2 (en) 2020-06-30
IL290166A (en) 2022-03-01
EP3394095A4 (en) 2019-08-14
IL259583B (en) 2022-03-01
JP2019504043A (ja) 2019-02-14

Similar Documents

Publication Publication Date Title
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
PH12018501378A1 (en) Compositions and methods for the treatment of hemoglobinopathies
PH12019500494A1 (en) Formulations of (r)-2-amino-3-phenylpropyl carbamate
MX2016011110A (es) Composiciones anti-espuma.
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
PH12016501441A1 (en) Chimeric alkaline phosphate-like proteins
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
AU2015287674B2 (en) Topical antiviral compositions and methods of using the same
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MY193650A (en) Extracellular matrix compositions
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
WO2015120138A3 (en) AGENTS THAT MODULATE RGMb-NEOGENIN-BMP SIGNALING AND METHODS OF USE THEREOF
MX2019010984A (es) Composiciones de sintecina y metodos de uso.
PH12017500836A1 (en) Transdermal formulations
MX2018016037A (es) Variantes de lipasa y composiciones que comprenden tensioactivo y variante de lipasa.
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
PH12017501022B1 (en) Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same
PH12018502233A1 (en) ErbB INHIBITORS AND USES THEREOF
MY191337A (en) Compositions for the treatment of hypertension and/or fibrosis
JOP20200126B1 (ar) طرق استخدام وتركيبات تحتوي على دولاجلوتيد
PH12016501838A1 (en) Compounds and their methods of use
GEP201706795B (en) Hexahydrofuropyrroles as pde1 inhibitors
MX383947B (es) Composiciones de colágeno 7 y métodos para usar las mismas.
PH12018501166B1 (en) Concentrated gibberellin solution formulations
MY182818A (en) Compositions for the treatment of fibrosis and fibrosis-related conditions